Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HSCS NASDAQ:IINN NASDAQ:IRIX NASDAQ:PSTV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHSCSHeartSciences$3.92-5.8%$3.82$2.36▼$6.47$4.50M2.57125,392 shs31,184 shsIINNInspira Technologies OXY B.H.N.$1.41-4.1%$0.83$0.40▼$1.65$18.55M2.24608,562 shs696,210 shsIRIXIRIDEX$1.26-2.3%$0.99$0.78▼$2.14$21.66M0.5757,227 shs413,025 shsPSTVPlus Therapeutics$0.37-3.0%$0.34$0.16▼$2.31$19.53M0.6910.69 million shs7.24 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHSCSHeartSciences+5.32%-27.40%+11.83%+25.87%+4.00%IINNInspira Technologies OXY B.H.N.+7.30%+7.30%+101.37%+150.72%+17.60%IRIXIRIDEX+20.56%+25.24%+32.48%+26.47%-36.45%PSTVPlus Therapeutics+18.21%+9.12%+24.11%-41.85%-78.66%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHSCSHeartSciences2.2125 of 5 stars3.52.00.00.02.20.01.3IINNInspira Technologies OXY B.H.N.2.2599 of 5 stars3.53.00.00.02.21.70.0IRIXIRIDEX1.0868 of 5 stars0.04.00.00.03.31.70.0PSTVPlus Therapeutics1.7138 of 5 stars3.32.00.00.02.50.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHSCSHeartSciences 3.00Buy$13.00231.63% UpsideIINNInspira Technologies OXY B.H.N. 3.00Buy$2.0041.84% UpsideIRIXIRIDEX 0.00N/AN/AN/APSTVPlus Therapeutics 2.50Moderate Buy$10.832,816.11% UpsideCurrent Analyst Ratings BreakdownLatest HSCS, IINN, IRIX, and PSTV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025PSTVPlus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.50 ➝ $3.006/25/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold$9.006/5/2025PSTVPlus TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $20.506/2/2025IINNInspira Technologies OXY B.H.N.Litchfield Hills ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy6/2/2025IINNInspira Technologies OXY B.H.N.Litchfield Hills ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$2.005/5/2025PSTVPlus TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/5/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/21/2025PSTVPlus TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$19.00 ➝ $20.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHSCSHeartSciences$20K211.68N/AN/A$11.16 per share0.35IINNInspira Technologies OXY B.H.N.N/AN/AN/AN/A$0.34 per shareN/AIRIXIRIDEX$48.67M0.43N/AN/A$0.13 per share9.69PSTVPlus Therapeutics$5.82M3.26N/AN/A($1.52) per share-0.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHSCSHeartSciences-$6.61M-$7.48N/AN/AN/AN/A-178.80%-109.28%8/4/2025 (Estimated)IINNInspira Technologies OXY B.H.N.-$11.05MN/A0.00∞N/AN/AN/AN/AN/AIRIXIRIDEX-$8.91M-$0.43N/A∞N/A-14.61%-290.57%-22.86%8/6/2025 (Estimated)PSTVPlus Therapeutics-$12.98M-$2.94N/AN/AN/A-520.90%N/A-202.73%8/13/2025 (Estimated)Latest HSCS, IINN, IRIX, and PSTV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025PSTVPlus Therapeutics-$0.12N/AN/AN/A$1.08 millionN/A8/4/2025N/AHSCSHeartSciences-$2.51N/AN/AN/AN/AN/A5/30/2025Q1 2025PSTVPlus Therapeutics-$0.17-$0.56-$0.39-$1.19$1.11 million$1.06 million5/13/2025Q1 2025IRIXIRIDEX-$0.10-$0.10N/A-$0.10$12.10 million$11.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHSCSHeartSciencesN/AN/AN/AN/AN/AIINNInspira Technologies OXY B.H.N.N/AN/AN/AN/AN/AIRIXIRIDEXN/AN/AN/AN/AN/APSTVPlus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHSCSHeartSciencesN/A1.020.83IINNInspira Technologies OXY B.H.N.0.092.021.89IRIXIRIDEX4.281.951.27PSTVPlus TherapeuticsN/A1.031.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHSCSHeartSciences17.24%IINNInspira Technologies OXY B.H.N.12.72%IRIXIRIDEX20.10%PSTVPlus Therapeutics3.28%Insider OwnershipCompanyInsider OwnershipHSCSHeartSciences1.80%IINNInspira Technologies OXY B.H.N.29.40%IRIXIRIDEX7.40%PSTVPlus Therapeutics3.76%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHSCSHeartSciences101.08 million1.06 millionNot OptionableIINNInspira Technologies OXY B.H.N.2012.62 million8.91 millionNot OptionableIRIXIRIDEX12016.79 million15.55 millionOptionablePSTVPlus Therapeutics2051.00 million49.08 millionNot OptionableHSCS, IINN, IRIX, and PSTV HeadlinesRecent News About These CompaniesPlus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal MetastasesJuly 15 at 8:23 AM | finance.yahoo.comPlus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal MetastasesJuly 15 at 7:30 AM | globenewswire.comPlus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases ConferenceJuly 10, 2025 | globenewswire.comPlus Therapeutics Initiates ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases TreatmentJuly 8, 2025 | quiverquant.comQPlus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal MetastasesJuly 8, 2025 | globenewswire.comPSTV - Plus Therapeutics Inc Trailing Returns - MorningstarJuly 2, 2025 | morningstar.comMPlus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal MetastasesJune 30, 2025 | globenewswire.comPlus Therapeutics Provides Business Update on CNSide Diagnostics SubsidiaryJune 26, 2025 | globenewswire.comPlus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ETJune 25, 2025 | globenewswire.comPlus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain CancerJune 25, 2025 | globenewswire.comPlus Therapeutics Restructures Financing to Eliminate Potential Dilution of 1.5 Billion SharesJune 24, 2025 | quiverquant.comQPlus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity FinancingJune 24, 2025 | globenewswire.comPlus (PSTV) Upgraded to Buy: Here's WhyJune 19, 2025 | zacks.comPlus Therapeutics Modifies Security Holders’ RightsJune 17, 2025 | tipranks.comPlus Therapeutics Reports First Quarter Financial Results and Recent Business HighlightsMay 30, 2025 | finance.yahoo.comPlus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue EstimatesMay 30, 2025 | zacks.comPlus Therapeutics, Inc. Reports Q1 2025 Financial Results and Updates on REYOBIQ™ Trials and CNSide® Assay Platform ProgressMay 30, 2025 | quiverquant.comQPlus Therapeutics Reports First Quarter Financial Results and Recent Business HighlightsMay 30, 2025 | globenewswire.comPlus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed ...May 23, 2025 | gurufocus.comPlus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-QMay 23, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHSCS, IINN, IRIX, and PSTV Company DescriptionsHeartSciences NASDAQ:HSCS$3.92 -0.24 (-5.77%) Closing price 04:00 PM EasternExtended Trading$3.98 +0.06 (+1.66%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.Inspira Technologies OXY B.H.N. NASDAQ:IINN$1.41 -0.06 (-4.08%) Closing price 04:00 PM EasternExtended Trading$1.40 0.00 (-0.35%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. Inspira Technologies Oxy B.H.N. Ltd. was incorporated in 2018 and is headquartered in Ra'annana, Israel.IRIDEX NASDAQ:IRIX$1.26 -0.03 (-2.33%) Closing price 04:00 PM EasternExtended Trading$1.27 +0.01 (+0.79%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.Plus Therapeutics NASDAQ:PSTV$0.37 -0.01 (-3.00%) Closing price 04:00 PM EasternExtended Trading$0.36 -0.01 (-3.63%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
